The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was ...

Shingles vaccine industry is projected to witness a CAGR of 10.1% during the period 2025-2034. This growth can be attributed ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Live-attenuated respiratory syncytial virus (RSV) vaccines are highly immunogenic among HIV-exposed uninfected (HEU) pediatric patients, according to results of a study published in Open Forum ...

Live attenuated vaccines are antigenic substances composed of a viable (living) pathogen, such as a virus or bacterium. The pathogen is altered so that it is less virulent or avirulent (attenuated).

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, ...

Researchers at Baylor College of Medicine and collaborating institutions have improved our understanding of how rotavirus, ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...